Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of subcutaneous homoharringtonine in accelerated-phase CML refractory or relapsed on imatinib
2005-000813-36Phase 2Completed
- Sponsor
- Stragen
- Start
- Aug 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine in chronic myelogenous leukemia (CML), sponsored by Stragen. Primary endpoint: Haematological response rate at end of induction. Started Aug 2005; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2005-000813-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000813-36.